If you got a question, look no further.
We post the most common questions
in our FAQ section.
Please fill in the form below to receive a Free Sample of the Report.
Two recessions in a decade, financial austerity, and unprecedented pressure
to prove product value to all stakeholders. There is no question that the pharma
game has changed in the new “Outcomes Era”, in which health economics and
outcomes research (HEOR) departments have moved from the background to the
But how is pharma handling the new pressures to develop products that not only
deliver blockbuster revenue but real world health outcomes, too? Are pharma
companies truly integrating health outcome values into product development or
merely paying lip-service?
In a rare and comprehensive insight into thriving in the “Outcomes Era”,
Value-driven Pharma: Integrating health outcomes across the product lifecycle
tackles the issues that have not been publicly addressed in full. The report
first looks at the current relationship between pharma and stakeholders, against
a backdrop of economic recession. It also examines the disconnect between
pharma's pledge to build value-driven products whilst failing to instil health
outcome values at the critical early development stages. Filled with invaluable
information from key industry insiders, the dossier is essential reading for R&D
or medical directors, CEOs, heads of managed markets and anyone else interested
in steering towards success in a tumultuous economic age.
Key Report Features
Filled with compelling and important insights into an evolving market, the
-Detailed examination of the integration of health outcomes initiatives into drug
discovery and early stage development-Advice on how to tailor health outcomes data to specific payers-Insight on best practices for enhancing relationships while overcoming payer
skepticism of the industry-Up-to-date comparison of companies’ efforts in launching health outcomes
initiatives, as well as an analysis of their practices-A case study detailing the Economic Perspectives Implemented in Clinical
Development (EPIC) from UCB Pharma.
Attitudes toward drug reimbursement have been shaped by economics. In
Value-driven Pharma: Integrating health outcomes across the product lifecycle,
-Understand the importance of endorsing a comprehensive approach to health
outcomes from the earliest stages of product development-Gain insight into devising strategies that incorporate health outcomes
initiatives from drug discovery to market rollout-Understand how to approach payers on a case-by-case basis, tailor data and
prioritise transparency-Be able to develop strategies that align health outcome initiatives across a
number of teams, from managed markets professionals to health outcome liaisons
Jonathan Plumb, Head, Market Access & Pricing, CNS at UCB Pharma
“The need to be innovative in terms of bringing added value to the customer is
clear. It was always there, but there was a certain tolerance, shall we say, of
me-toos and second-, third- and fourth-in-class for any given indication. Now,
that level of tolerance is definitely gone.”
Ashok Bhaseen, VP Marketing and Sales at Pediapharm and President of Thyroid
“In this day and age it is all about outcomes. I don't talk about value because
value has become a dirty word — overused and under-delivered. Outcomes, by
contrast, is a word that speaks for itself.”
Siva Narayanan, Senior Vice President, Evidence Generation, Value and Access at
“Value is the mantra right now. We have to demonstrate value in three different
ways: Economic value, clinical value and humanistic value — the value from the
perspective of payers, physicians and patients.”
Key Questions Answered
-How do pharma companies compare in relation to health outcome initiatives?-Is there a demonstrable benefit to starting health outcomes research in early
stages, as opposed to post-launch?-What can companies do to integrate health outcomes into R&D, in order to ensure
real-world value?-How can companies with a silo culture integrate aligned health outcomes into a
matrix?-How can data be tailored and leveraged with payers?
-Ashok Bhaseen, Vice President Marketing and Sales at Pediapharm & President of Thyroid Federation International-Babak Boroojerdi, Vice President, PST Liaison CNS Practice, at UCB Pharma-Tommy Bramley, Senior Vice President of Scientific Consulting, Xcenda-Klaus Eckhardt, Medical Director, CNS Therapy Area at UCB Pharma-Carl Mamay, Head of Managed Markets at LEO Pharma-Siva Narayanan, Senior Vice President, Evidence Generation, Value and Access at Ipsos-Jonathan Plumb, Head, Market Access & Pricing, CNS at UCB Pharma-Emmanuelle Senior, Associate Director, Global Market Access & Pricing, CNS at UCB Pharma-Erik Smets, Head, Global Outcomes & Access, Immunology at UCB Pharma-Robin Winter-Sperry, President & CEO, Scientific Advantage
As the economic fallout of two recessions in a decade impacts pharma, the
industry is focusing its attention on health outcomes initiatives. In this
report, you will discover:
-The value of starting health outcomes research early—very early—and not after a
product is launched and in need of ‘dressing up.’-The importance of innovation in both implementing and integrating health
outcomes initiatives-The most current industry data, including a case study of the Economic
Perspectives Implemented in Clinical Development (EPIC) initiative from UCB
Pharma.-Why it’s important to overcome a silo mentality and work within a matrix
approach to ensure alignment of health outcomes initiatives.